Figure 8. The function of miR-139-5p inhibitors depends on PDGF-B and VEGF expression. (A) The different treated ECFCs were lysed and used to perform ChIP experiments. C-jun antibody was used to bind the VEGF promoter while a special VEGF primer was used to detect the binding vegf or gDNA vegf in the ChIP or input DNA. The input VEGF was the PCR product of total DNA without immunoprecipitation + c-jun antibody, which was used as the normalization control. The ChIP VEGF was the PCR product of the DNA bound to the c-jun antibody. (N=3) *P < .05 versus control. (B) Tube formation of diabetic-derived ECFCs transfected with miR-139-5p inhibitors with or without anti-KDR/anti-PDGF treatment was observed. The photos were captured by a 40X microscope. (N=3) *P < .05. Data shown in the graphs represent mean ± standard deviation.